Journal of Clinical Epidemiology
Volume 52, Issue 12 , Pages 1173-1186 , December 1999

Design of A Case Control Etiologic Study of Sarcoidosis (ACCESS)

  • ACCESS Research Group

      Affiliations

,Accepted 28 June 1999.

References 

  1. Hunninghake GW, Crystal RG. Pulmonary sarcoidosis (A disorder mediated by excess helper T-lymphocyte activity at sites of disease activity). N Engl J Med. 1981;305:429–434
  2. James DG, Hosoda Y. Epidemiology. In:  James DG editors. Sarcoidosis and Other Granulomatous Disorders. New York, NY: Marcel Dekker; 1994;
  3. Thomas PD, Hunninghake GW. Current concepts of the pathogenesis of sarcoidosis. Am Rev Respir Dis. 1987;135:747–760
  4. Keller AZ. Hospital, age, racial, occupational, geographical, clinical and survivorship characteristics in the epidemiology of sarcoidosis. Am J Epidemiol. 1971;94:222–230
  5. Cooch JW. Sarcoidosis in the United States Army, 1952 through 1956. Am Rev Respir Dis. 1961;84:S103–S108
  6. Sartwell PE, Edwards LB. Epidemiology of sarcoidosis in the U.S. Navy. Am J Epidemiol. 1974;99:250–257
  7. Hosoda Y, Hiraga Y, Odaka M, et al.  A cooperative study of sarcoidosis in Asia and Africa (Analytic epidemiology). Ann NY Acad Sci. 1976;278:355–367
  8. Siltzbach LE, James DG, Neville E, et al.  Course and prognosis of sarcoidosis around the world. Am J Med. 1974;57:847–852
  9. Sharma OP. A call for epidemiological research in sarcoidosis. Sarcoidosis. 1992;9:77–78
  10. Yamamoto M, Sharma OP, Hosoda Y. Special report (The 1991 descriptive definition of sarcoidosis). Sarcoidosis. 1992;9:S33–S34
  11. Baughman RP, Winget DW, Bowen EH, Lower EE. Predicting respiratory failure in sarcoidosis patients. Sarcoidosis, Vasculitis and Diffuse Lung Diseases. 1997;14:154–158
  12. Schlesselman J. Case-control studies. Design, Conduct, Analysis. New York, NY: Oxford University Press; 1982.
  13. Waksberg J. Sampling methods for random digit dialing. J Am Stat Assoc. 1978;56:33–43
  14. Taubes G. Epidemiology faces its limits. Special News Report. Science. 1995;269:164–169
  15. Peterson B, George SL. Sample size requirements and length of study for testing interaction in a 2 × K factorial design when time-to-failure is the outcome. Controlled Clinical Trials. 1993;14:511–522
  16. Breslow L, Day NE. Statistical Methods in Cancer Research. Volume 1—The analysis of case control studies. Lyon, France: International Agency for Research on Cancer; 1980;
  17. James DG, Neville E, Piyasena KHG, Walker AN, Hamlyn AN. Possible genetic influences in familial sarcoidosis. Post Med J. 1974;50:664–670
  18. Sharma OP, Neville E, Walker AN, James DG. Familial sarcoidosis (A possible genetic influence). Ann NY Acad Sci. 1976;278:386–400
  19. James DG, Williams WG. Sarcoidosis and Other Granulomatous Diseases. Philadelphia, PA: WB Saunders; 1985;
  20. Harrington DW, Major M, Rybicki B, Popovich J, Maliarik M, Iannuzzi MC. Familial analysis of 91 families. Sarcoidosis. 1994;11:240–243
  21. Lander ES, Schork NJ. Genetic dissection of complex traits. Science. 1994;265:2037–2048
  22. Khoury MJ, Beaty TH, Cohen BH. Fundamentals of Genetic Epidemiology. New York, NY: Oxford University Press; 1993;
  23. Pasturenzi L, Martinetti M, Cuccia M, Cipriani A, Semanzato G, Luisetti M. HLA class I, II and III polymorphism in Italian patients with sarcoidosis. The Pavia-Padova Sarcoidosis Study Group. Chest. 1993;104:1170–1175
  24. Martinetti M, Tinelli C, Kolek V, et al.  “The sarcoidosis map” (A joint survey of clinical and immunologic finding in two European countries). Am J Respir Crit Care Med. 1995;152:557–564
  25. Ishihara M, Inoko H, Suzuki K, et al.  HLA class II genotyping of sarcoidosis patients in Hokkaido by PCR-RFLP. Jap J Ophthalmol. 1996;40:540–543
  26. Babbitt BP, Allen PM, Matsueda G, Haber E, Unanue ER. Binding of immunogenic peptides to a histocompatibility molecules. Nature. 1985;317:359–361
  27. Dyer PA, Jawaheer D, Ollier B, Pouton K, Sinnott P, Thomson W. HLA allele detection using molecular techniques. Disease Markers. 1993;11:145–160
  28. Boros DL. Mechanisms of granuloma formation in the lung. In:  Daniele RPEd editors. Immunology and Immunologic Lung Diseases of the Lung. Boston, MA: Blackwell Scientific Pub; 1988;
  29. Semenzato G, Chilosi M, Ossi E, et al.  Bronchoalveolar lavage and lung histology (Comparative analysis of inflammatory and immunocompetent cells in patients with sarcoidosis and hypersensitivity pneumonitis). Am Rev Respir Dis. 1985;132:400–404
  30. Newman LS. Beryllium disease and sarcoidosis (Clinical and laboratory links). Sarcoidosis. 1995;12:7–19
  31. DeVuyst P, Dumortier P, Schandene L, Estenne M, Verhest A, Yernault J-C. Sarcoid-like lung granulomatosis induced by aluminum dusts. Am Rev Respir Dis. 1987;135:493–497
  32. Redline S, Bama BP, Tomashefski JF, Abraham JL. Granulomatous disease associated with pulmonary deposition of titanium. Br J Industr Med. 1986;43:652–656
  33. Skelton HG, Smith KJ, Johnson FV, Cooper CR, Tyler WF, Lupton GP. Zirconium granuloma resulting from an aluminum zirconium complex (A previously unrecognized agent in the development of hypersensitivity granulomas). J Am Acad Dermatol. 1993;28:874–876
  34. Forst LS, Abraham J. Hypersensitivity pneumonitis presenting as sarcoidosis. Br J Indust Med. 1993;50:497–500
  35. Gordis L. Sarcoidosis. In: Epidemiology of Chronic Lung Diseases in Children.. Baltimore, MD: The Johns Hopkins University Press; 1973;
  36. Pattishall EN, Strope GL, Spinola SM, Denny FW. Childhood sarcoidosis. J Pediatr. 1986;108:169–177
  37. Bardinas F, Morera J, Fit'e E, Plasencia A. Seasonal clustering of sarcoidosis (Letter). Lancet. 1989;2:455–456
  38. Henke CE, Henke G, Elveback LR, Beard CM, Ballard DJ, Kurland LT. The epidemiology of, sarcoidosis in Rochester, Minnesota (A population-based study of incidence and survival). Am J Epidemiol. 1986;123:840–845
  39. Selroos O. The frequency, clinical picture and prognosis of pulmonary sarcoidosis in Finland. Acta Med Scand Suppl. 1969;503:3–73
  40. Parkes SA, Baker SB, Bourdillon RE, Murray CR, Rakshit M. Epidemiology of sarcoidosis in the Isle of Man—1 (A case controlled study). Thorax. 1987;42:420–426
  41. Buck AA. Epidemiologic investigators of sarcoidosis. IV. Discussion and summary. Am J Hyg. 1961;74:189–202
  42. Gentry JT, Nitowsky HM, Michael M. Studies on the epidemiology of sarcoidosis in the United States. The relationship to soil areas and to urban-rural residence. J Clin Invest. 1955;34:1839–1856
  43. Terris M, Chaves AD. An epidemiologic study of sarcoidosis. Am Rev Respir Dis. 1966;94:50–55
  44. Cummings MM, Dunner E, Williams JH. Epidemiologic and clinical observations in sarcoidosis. Ann Intern Med. 1959;50:879–890
  45. Dunner E, Williams JH. Epidemiology of sarcoidosis in the United States. Am Res Respir Dis. 1961;84:S163–S168
  46. Gundelfinger BF, Britten SA. Sarcoidosis in the United States Navy. Am Rev Respir Dis 1961; 84; S109–S115.
  47. Bresnitz EA, Strom BL. Epidemiology of sarcoidosis. Epidemiol Rev. 1983;5:124–156
  48. Kern DG, Neill MA, Wrenn DS, Varone JC. Investigation of a unique time-space cluster of sarcoidosis in fire fighters. Am Rev Resp Dis. 1993;148:974–980
  49. Parkes SA, Baker SB, Bourdillon RE, et al.  Incidence of sarcoidosis in the Isle of Man. Thorax. 1985;40:284–287
  50. Edmonstone WM. Sarcoidosis in nurses (Is there an association?). Thorax. 1988;43:342–343
  51. Hills SE, Parkes SA, Baker SB. Epidemiology of sarcoidosis in the Isle of Man—2 (Evidence for space–time clustering). Thorax. 1987;42:427–430
  52. Sharma OP, Kadakia D. Etiology of sarcoidosis. Seminars Resp Med. 1986;8:95–102
  53. Stewart IC, Davidson NM. Clustering of sarcoidosis. Thorax. 1982;37:398–399
  54. Mitchell DN, Rees RJ, Goswami KK. Transmissible agents from human sarcoid and Crohn's disease tissues. Lancet. 1976;2:761–765
  55. Heyll A, Meckenstock G, Aul C, et al.  Possible transmission of sarcoidosis via allogenic bone marrow transplantation. Bone Marrow Transplan. 1994;14:161–164
  56. Burke WM, Keogh A, Maloney PJ, et al.  Transmission of sarcoidosis via cardiac transplantation (Letter). Lancet. 1990;336:1579
  57. Kazerooni EA, Cascade PN. Recurrent miliary sarcoidosis after lung transplantation (Letter). Radiology. 1995;194:913
  58. Martinez FJ, Orens JB, Deeb M, Brunsting LA, Flint A, Lynch JP. Recurrence of sarcoidosis following bilateral allogenic lung transplantation. Chest. 1994;106:1597–1599
  59. Popper HH, Winter E, Hofler G. DNA of mycobacterium tuberculosis in formalin-fixed, paraffin-embedded tissue in tuberculosis and sarcoidosis detected by polymerase chain reaction. Am J Clin Pathol. 1994;101:738–741
  60. Mangiapan G, Hance AJ. Mycobacteria and sarcoidosis (An overview and summary of recent molecular biological data). Sarcoidosis. 1995;12:20–37
  61. Bisaccia E, Scarborough DA, Carr RD. Cutaneous sarcoid granuloma formation in resolving herpes zoster scars. Arch Dermatol. 1983;119:788–789
  62. Nikkels AF, Debrus S, Delvenne P, Sadzot-Delvaux C, Piette J, Rentier B, et al. Viral glycoproteins in herpes viridae granulomas. Am J Dermatopath. 1994;16:588–592
  63. Su WP, Kuechle MK, Peters MS, Muller SA. Palisading granulomas caused by infectious diseases. Am J Dermatopath. 1992;14:211–215
  64. Ehlers S, Mielke ME, Hahn H. The mRNA-phenotype of granuloma formation in CD4+T-cell-associated cytokine gene expression during primary murine listeriosis. Immunobiol. 1994;191:432–440
  65. Cho C, Linscheer WG, Hirschkom MA, Ashutosh K. Sarcoid like granulomas as an early manifestation of Whipple's disease. Gastroenterology. 1984;87:941–947
  66. Southern JF, Moscicki RA, Magro C, Dickersin GR, Fallon JT, Bloch KJ. Lymphedema, lymphocytic myocarditis, and sarcoid-like granulomatosis. Manifestations of Whipple's disease. JAMA. 1989;261:1467–1470
  67. Van Etta LL, Filice GA, Ferguson RM, Gerding DN. Corynebacterium egia (A review of 12 cases of human infection). Rev Infect Dis. 1983;5:1012–1017
  68. Langenberg A, Yen TS, Leboit PE. Granulomatous vasculitis occurring after cutaneous herpes zoster despite absence of the viral genome. J Am Acad Derm. 1991;24:429–433
  69. Williams WR, Davies BH. Pseudo-leptospires in bronchoalveolar lavage fluid and blood cell culture. J Exp Path. 1986;67:167–170
  70. Wang N, Schraufnagal DE, Sampson MG. The tadpole-shaped structures in human nonnecrotizing granulomas. Am Rev Resp Dis. 1981;123:560–564
  71. Chadarevian J, Raphael SA, Murphy GF. Histologic, ultrastructural and immunocytochemical features of the granulomas seen in a child with the syndrome of familial granulomatous arthritis, uvietis, and rash. Arch Path Lab Med. 1992;117:1050–1052
  72. Murakami S, Takahashi Y, Yoshida S, et al.  Highly sensitive detection of viral RNA genomes in blood specimens by an optimized reverse transcription-polymerase chain reaction. J Med Virol. 1994;43:175–181
  73. Goodman JL, Bradley JF, Ross AE, et al.  Bloodstream invasion in early lyme disease (Results from a prospective, controlled, blinded study using the polymerase chain reaction). Am J Med. 1995;99:6–12
  74. Schluger NW, Condos R, Lewis S, Rom WN. Amplification of DNA of mycobacterium tuberculosis from peripheral blood of patients with pulmonary tuberculosis. Lancet. 1994;344:232–233
  75. Chryssanthou E, Andersson B, Petrini B, Lofdahl S, Tollemar J. Detection of candida albicans DNA in serum by polymerase chain reaction. Scand J Infect Dis. 1994;26:479–485
  76. Stackebrandt E, Woese CR. A definition of the domains archaea, bacteria and eukarya in terms of small subunit ribosomal RNA characteristics. System Appl Micro. 1991;14:305–310
  77. Schmidt TM, Relman DA. Phylogenetic identification of uncultured pathogens using ribosomal RNA sequences. Meth Enzymol. 1994;235:205–222
  78. Rowley AH, Wolinsky SM, Relman DA, et al.  Search for highly conserved viral and bacterial nucleic acid sequences corresponding to an etiologic agent of Kawasaki disease. Pediatr Res. 1994;36:567–571
  79. Relman DA, Schmidt TM, MacDermott RP, Falkow S. Identification of uncultured bacillus of Whipple's disease. New Eng J Med. 1992;327:293–301
  80. Liang P, Pairdee AB. Differential display of eukaryotic messenger RNA by means of the polymerase chain reaction. Science. 1992;257:967–971
  81. Sunday MD. Differential Display RT-PCR for identifying novel gene expression in the lung. Am J Physiol. 1995;269:1273–1284
  82. Williams RH, Nickerson DA. Skin reactions in sarcoid. Proc Soc Biol Med. 1941;33:403–405
  83. Appel B, Nickerson quoted) DA. Sarcoid. Arch Dermatol Syphilol. 1941;43:172–173
  84. Kveim A. Em ny og specifikk kutans reaksjon ved Boecks sarcoid, en forelobig meddelse. Nord Med. 1941;9:169–172
  85. Danbolt N. On skin test with sarcoid-tissue-suspension (Kveim's Reaction). Acta Derm Venereol. 1951;31:184–193
  86. Putkonen T. Uber die Intrakutanreaktion von Kveim (KcR) bei lymphoganulomatosis benigna und uber das Bild dieser Krankheit im Lichte der Reaktionsergebnisse. Acta Derm Venereol. 1943;23:1–194
  87. Nelson CT. Kveim reaction in sarcoidosis. Arch Dermatol Syphilol. 1949;60:337–389
  88. Siltzbach LE. The Kveim test in sarcoidosis (A study of 750 patients). JAMA. 1961;178:476–482
  89. Siltzbach LE. The Kveim test in tuberculosis, beryllium diseases, leprosy and sarcoidosis (Abstract). Am Rev Respir Dis. 1964;90:308
  90. Siltzbach LE. An international Kveim test study: 1960–1966. In: Turiaf J, Chabot J, Eds. La Sarcoidose. Rapports de la IV Conference Internationale. Paris, France: Masson & Cie 1967; 201–212.
  91. Israel HL, Goldstein RA. Relation of Kveim-antigen reaction to lymphadenopathy (Study of sarcoidosis and other diseases). N Engl J Med. 1971;284:345–349
  92. Karlish AJ, Cox EV, Hamspon F, et al.  Kveim test in Crohn's disease (Letter). Lancet. 1970;2:977–978
  93. Bringle C, Löfgren S. Relationship Between Sarcoidosis and Collagen Diseases: Preliminary Report. La Sarcoidosis. Geneva, Switzerland: Reports of the European Symposium on Sarcoidosis; 1972; 34.
  94. Teirstein AS. The Kveim-Siltzbach test. Clin Derm. 1986;4:154–164
  95. Teirstein AS, Brown LK. The Kveim-Siltzbach test in 1987. In:  Grassi C,  Rizatto G,  Pozzi E editor. Proceedings of the XI World Congress of Sarcoidosis and Other Granulomatous Disorders. Amsterdam, The Netherlands: Elsevier Sci Pub; 1988;
  96. Teirstein AS. The Kveim-Siltzbach test in sarcoidosis. In:  Lieberman J editors. Sarcoidosis. Orlando, FL, USA: Grune and Stratton; 1985;
  97. Adams DO. The granulomatous inflammatory response. Am J Path. 1976;84:164–191
  98. Epstein W. Granuloma formation in man. Pathol Ann. 1977;7:1–30
  99. Boros DL. Immunoregulation of granuloma formation in murine schistosomiasis mansoni. Ann NY Acad Sci. 1986;465:313–323
  100. Cohen Z, et al. The distribution of Kveim activity in subcellular fractions from sarcoid lymph nodes. In: Turiaf J, Chabot J, Eds. La Sarcoidose. Rapports de la IV Conference Internationale. Paris, France: Masson & Cie, 1967; 141–149.
  101. Siltzbach LE, Ruttenberg M. Chemical and physical characteristics of the active principle of Kveim suspensions. In: Levinski L, Macholda F, Eds. Proceedings of the V International Congress on Sarcoidosis. Prague, Czechoslovakia: Univ Karlova, 1971; 371–374.
  102. Lyons DJ, Donald S, Mitchell DN, Asherson GL. Chemical inactivation of the Kveim reagent. Respiration. 1992;59:22–26
  103. Kataria YP, Park HK. Dynamics and mechanism of sarcoidal granuloma (detecting T-cell subsets, non-T-cells, and immunoglobulins in biopsies at varying interval of Kveim-Siltzbach test site). Ann NY Acad Sci. 1986;465:221–232
  104. Mishra BB, Poulter LW, Janossy G, et al.  The distribution of lymphoid and macrophage like cell subsets of sarcoid and Kveim granulomata; possible mechanism of negative PPD reaction in sarcoidosis. Clin Exp Immunol. 1983;54:705–715
  105. Munro CS, Mitchell DN, Poulter LW, Cole PJ. Early cellular responses to intradermal injection of Kveim suspension in normal subjects and those with sarcoidosis. J Clin Pathol. 1986;39:176–182
  106. Tüzüner N, Ulku B, Uraz S, Gungen G, Demirci S, Celikoglu S. The distribution of T-cell subsets of Kveim and sarcoid granulomata (An immunohistological investigation of blood, Kveim test sites and sarcoid tissue lesions from 16 patients). Sarcoidosis. 1991;8:14–18
  107. Daniele RP, Dauber JH, Roseman MD. Immunologic abnormalities in sarcoidosis. Ann Intern Med. 1980;92:406–416
  108. Yeager H, Williams MC, Beekman JF. Sarcoidosis (analysis of cells obtained by bronchial lavage). Am Rev Respir Dis. 1977;116:951–955
  109. DuBois RM, Kirby M, Balbi B, et al.  T-lymphocytes that accumulate in the lung in sarcoidosis have evidence of recent stimulation of the T-cell antigen receptor. Am Rev Respir Dis. 1992;145:1205–1211
  110. Moller DR, Konishi K, Kirby M, Balbi B, Crystal RG. Bias toward use of a specific T cell receptor β-chain variable region in a subgroup of individuals with sarcoidosis. J Clin Invest. 1988;82:1183–1191
  111. Grunewald J, Janson CH, Eklund A, et al.  Restricted V2.3 gene usage by CD4+ T lymphocytes in bronchoalveolar lavage fluid from sarcoidosis patients correlates with HLA-DR3. Eur J Immunol. 1992;22:129–135
  112. Balbi B, Moller DR, Kirby M, Holroyd KJ, Crystal RG. Increased numbers of T lymphocytes with γδ-positive antigen receptors in a subgroup of individuals with pulmonary sarcoidosis. J Clin Inv. 1990;85:1353–1361
  113. Tamura N, Holroyd KJ, Banks T, Kirby M, Okayama H, Crystal RG. Diversity in junctional sequences associated with the common human V gamma 9 and V delta 2 gene segments in normal blood and lung compared with the limited diversity in a granlomatous disease. J Exp Med. 1990;172:169–181
  114. Forrester JM, Newman LS, Wang Y, King TE, Kotzin BL. Clonal expansion of lung Vδ1+ T cells in pulmonary sarcoidosis. J Clin Invest. 1993;91:292–300
  115. Forman JD, Klein JT, Silver RF, et al.  Selective activation and accumulation of oligoclonal Vβ-specific T cells in active pulmonary sarcoidosis. J Clin Invest. 1994;94:1533–1542
  116. Forrester JM, Wang Y, Ricalton N, Fitzgerald JE, Loveless J, Newman LS, et al. TCR expression of activated T-cell clones in the lungs of patients with pulmonary sarcoidosis. J Immunol. 1994;153:4291–4302
  117. Silver RS, Crystal RG, Moller DR. Limited heterogeneity of biased T-cell receptor Vβ gene usage in lung but not blood T cells in active pulmonary sarcoidosis. Immunol. 1996;88:516–523
  118. Klein JT, Horn TD, Forman JD, et al.  Selection of oligoclonal Vβ-specific T-cells in the intradermal response in Kveim-Siltzbach reagent in individuals with sarcoidosis. J Immunol. 1994;154:1450–1460
  119. Pinkston P, Bitterman PB, Crystal RG. Spontaneous release of interleukin-2 by lung T-lymphocytes in active pulmonary sarcoidosis. N Engl J Med. 1983;308:793–800
  120. Moller DR, Forman JD, Liu MC, et al.  Enhanced expression of IL-12 associated with Th1 cytokine profiles in active pulmonary sarcoidosis. J Immunol. 1996;156:4952–4960
  121. Teirstein AS, Siltzbach LE, Berger J. Patterns of sarcoidosis in three population groups in New York City. Ann NY Acad Sci. 1976;276:371–376
  122. Zaki MH, Addrizzo JR, Patton JM, Murphy JJ. Further exploratory studies in sarcoidosis. An epidemiologic investigation to compare the prevalence of tuberculosis infection and/or disease among contacts of matched sarcoidosis and asthmatic patients. Am Rev Respir Dis. 1971;103:539–545
  123. Young RC, Titus-Dillon PY, Schneider ML, Shelton TG, Hackeny RL, Harden KA. Sarcoidosis in Washington, D.C. (Clinical observations in 105 black patients). Arch Intern Med. 1970;125:102–105
  124. Young RC, Hackney RL, Harden KA. Epidemiology of sarcoidosis (Ethnic and geographic considerations). J Natl Med Assoc. 1974;66:386–388
  125. Okada LM, Sparer G. Access to usual source of care by race and income in ten urban areas. J Comm Health. 1976;1:163–174
  126. Newacheck PW, Butler LH. Patterns of physician use among low-income, chronically ill persons. Med Care. 1983;21:981–989
  127. Kleinman JC, Gold M, Makuc D. Use of ambulatory medical care by the poor (Another look at equity). Med Care. 1981;19:1011–1029
  128. McHorney CA, Ware KE, Lu JF, Sherbourne CD. The MOS 36-item short form survey (SF-36) (III. tests of data quality, scaling assumptions, and reliability across diverse patient groups). Med Care. 1994;32:40–66
  129. RAND, Santa Monica CA. The RAND 36-item health survey 1.0. Health Economics 1993; 217–227.
  130. Ware JE, Sherbourne CD. The MOS-36 item short-form health survey (SF-36) (I. Conceptual framework and item selection). Med Care. 1992;30:473–483
  131. Swayzye S. Helping them cope. J Psychosoc Nurs & Men Heal Serv. 1991;29:35–37

☆ Members of the ACCESS Research Group are listed in Appendix 1.

☆☆ The content of this article does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government.

PII: S0895-4356(99)00142-0

Journal of Clinical Epidemiology
Volume 52, Issue 12 , Pages 1173-1186 , December 1999

Article Tools

* Image Usage & Resolution